These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12737421)

  • 21. Lawsuits anticipated on generic biologicals front.
    Fox JL
    Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
    [No Abstract]   [Full Text] [Related]  

  • 22. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
    Dorfman HL; Quinn VM; Brophy EA
    Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
    [No Abstract]   [Full Text] [Related]  

  • 23. Reorienting environmental health practice in Fiji: the potential in developing a National Environmental Health Action Plan.
    Powis B; Litidamu N; O'Leary Z
    Pac Health Dialog; 2003 Sep; 10(2):27-33. PubMed ID: 18181412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiperspirant drug products for over-the-counter human use; final monograph. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(110):34273-93. PubMed ID: 12795305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multisource drug policies in Latin America: survey of 10 countries.
    Homedes N; Ugalde A
    Bull World Health Organ; 2005 Jan; 83(1):64-70. PubMed ID: 15682251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The case for preemption of prescription drug failure-to-warn claims.
    Kim CH
    Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
    [No Abstract]   [Full Text] [Related]  

  • 27. Sandoz sues FDA over delay in first biogeneric approval.
    Fox JL
    Nat Biotechnol; 2005 Nov; 23(11):1327-8. PubMed ID: 16273046
    [No Abstract]   [Full Text] [Related]  

  • 28. Switching to generic: the need for physician and patient consent when substituting antiepileptic medication.
    Langdon EH
    J Contemp Health Law Policy; 2008; 25(1):166-95. PubMed ID: 19137751
    [No Abstract]   [Full Text] [Related]  

  • 29. [Generic drugs and substitution rights: Pandora's box?].
    Chalchat B
    Ann Pharm Fr; 1996; 54(6):284-6. PubMed ID: 9008905
    [No Abstract]   [Full Text] [Related]  

  • 30. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 31. Medicaid program; time limitation on record keeping requirements under the drug rebate program. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2004 Jan; 69(3):508-14. PubMed ID: 14968795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The draft Resolution on substances exclusively pharmaceutical (and the draft Resolution on medication indication)].
    Beudeker G
    Pharm Weekbl; 1967 Jun; 102(24):543-9. PubMed ID: 6077695
    [No Abstract]   [Full Text] [Related]  

  • 33. Requirements on content and format of labeling for human prescription drug and biological products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jan; 71(15):3921-97. PubMed ID: 16479698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pediculicide drug products for over-the-counter human use; amendment of final monograph. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Dec; 68(250):75414-8. PubMed ID: 14986677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Global health and university patents.
    Kapczynski A; Crone ET; Merson M
    Science; 2003 Sep; 301(5640):1629. PubMed ID: 14500943
    [No Abstract]   [Full Text] [Related]  

  • 36. Organ-specific warnings; internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; final monograph. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Apr; 74(81):19385-409. PubMed ID: 19507324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 'Soft medicine' is not always soft: the original sin of German drug legislation.
    Happle R
    Dermatology; 2007; 214(2):105-7. PubMed ID: 17341856
    [No Abstract]   [Full Text] [Related]  

  • 38. Substituting generic drugs: state roles.
    Cauchi R
    NCSL Legisbrief; 2009; 17(25):1-2. PubMed ID: 19526654
    [No Abstract]   [Full Text] [Related]  

  • 39. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.